Authors
Loading...
In vitro study reveals novel bivalent compounds binding human melatonin and histamine H3 receptors, highlighting potential dual-acting therapeutics for neurodegenerative diseases.
Pala et al. (2014) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: